BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 29968252)

  • 1. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression.
    Komor MA; de Wit M; van den Berg J; Martens de Kemp SR; Delis-van Diemen PM; Bolijn AS; Tijssen M; Schelfhorst T; Piersma SR; Chiasserini D; Sanders J; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; Carvalho B; Meijer GA; Jimenez CR; Fijneman RJA;
    Int J Cancer; 2020 Apr; 146(7):1979-1992. PubMed ID: 31411736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.
    Chang K; Willis JA; Reumers J; Taggart MW; San Lucas FA; Thirumurthi S; Kanth P; Delker DA; Hagedorn CH; Lynch PM; Ellis LM; Hawk ET; Scheet PA; Kopetz S; Arts J; Guinney J; Dienstmann R; Vilar E
    Ann Oncol; 2018 Oct; 29(10):2061-2067. PubMed ID: 30412224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus molecular subtype transition during progression of colorectal cancer.
    van de Weerd S; Torang A; Zwager LW; Koelink PJ; Koster J; Bastiaansen BA; Lammers V; Longobardi C; Roodhart JM; van Krieken JH; Farina Sarasqueta A; Dekker E; Medema JP
    J Pathol; 2023 Nov; 261(3):298-308. PubMed ID: 37681286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathological classification of colorectal cancer.
    Müller MF; Ibrahim AE; Arends MJ
    Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
    Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
    Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains.
    Berg KCG; Sveen A; Høland M; Alagaratnam S; Berg M; Danielsen SA; Nesbakken A; Søreide K; Lothe RA
    Oncogene; 2019 Aug; 38(33):6109-6122. PubMed ID: 31308487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles in genome instability-based classes of colorectal cancer.
    Barresi V; Cinnirella G; Valenti G; Spampinato G; Musso N; Castorina S; Condorelli DF
    BMC Cancer; 2018 Dec; 18(1):1265. PubMed ID: 30563495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
    Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
    Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression.
    Komor MA; Bosch LJ; Coupé VM; Rausch C; Pham TV; Piersma SR; Mongera S; Mulder CJ; Dekker E; Kuipers EJ; van de Wiel MA; Carvalho B; Fijneman RJ; Jimenez CR; Meijer GA; de Wit M
    J Pathol; 2020 Mar; 250(3):288-298. PubMed ID: 31784980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of ZG16 is associated with molecular and clinicopathological phenotypes of colorectal cancer.
    Meng H; Li W; Boardman LA; Wang L
    BMC Cancer; 2018 Apr; 18(1):433. PubMed ID: 29661177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
    Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
    Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
    [No Abstract]   [Full Text] [Related]  

  • 16. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Back to the Colorectal Cancer Consensus Molecular Subtype Future.
    Menter DG; Davis JS; Broom BM; Overman MJ; Morris J; Kopetz S
    Curr Gastroenterol Rep; 2019 Jan; 21(2):5. PubMed ID: 30701321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The consensus molecular subtypes of colorectal cancer.
    Guinney J; Dienstmann R; Wang X; de Reyniès A; Schlicker A; Soneson C; Marisa L; Roepman P; Nyamundanda G; Angelino P; Bot BM; Morris JS; Simon IM; Gerster S; Fessler E; De Sousa E Melo F; Missiaglia E; Ramay H; Barras D; Homicsko K; Maru D; Manyam GC; Broom B; Boige V; Perez-Villamil B; Laderas T; Salazar R; Gray JW; Hanahan D; Tabernero J; Bernards R; Friend SH; Laurent-Puig P; Medema JP; Sadanandam A; Wessels L; Delorenzi M; Kopetz S; Vermeulen L; Tejpar S
    Nat Med; 2015 Nov; 21(11):1350-6. PubMed ID: 26457759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.